Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**125I-tyr-3-octreotide** is a *radioiodinated analogue of the somatostatin receptor ligand octreotide*, specifically labeled with radioactive iodine-125 at the tyrosine-3 position. It is used primarily as a radiopharmaceutical tool for imaging and research purposes to detect and study somatostatin receptor-positive tumors, typically neuroendocrine tumors. Its mechanism of action is based on binding with high affinity to somatostatin receptors, particularly subtypes 2 and 5, allowing for the localization and characterization of tumors by imaging techniques. It is not used therapeutically for disease modification or symptom control but for diagnostic, localization, or research applications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 125I-tyr-3-octreotide.